At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AL101 Prior to Standard-of-Care Surgery in Patients With Notch Activated Adenoid Cystic Carcinoma (ACC)
In Brief
A Phase 1 clinical trial evaluating AL101 and Therapeutic Conventional Surgery for Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma. Completed, enrolled 13 participants across 1 site.
Signals
Detailed Summary
This phase Ib trial studies the side effects and possible benefits of AL101 before surgery in treating patients with notch activated adenoid cystic cancer. AL101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving AL101 before surgery may help to control adenoid cystic cancer that has a NOTCH pathway activation.
Study Details
Timeline
Arms & Interventions
Patients receive AL101 IV over 60 minutes QW for 6-8 weeks in the absence of disease progression or unacceptable toxicity. Within 24-72 hours after the last infusion of AL101, patients undergo surgery per standard of care. Patients may continue AL101 after surgery at the discretion of the study doctor.
Interventions
Given IV
Undergo standard of care surgery